We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Menopause authority guide
It is not that you don't love your partner. It is that your body is different — and there is more you can do than you've been told.
Reviewed by the kindr Health medical team · Last reviewed July 15, 2026
This page names things that most clinical visits skip. Both sides of intimacy — desire and physical comfort — are physiologically driven and physiologically treatable.
GSM is the current medical term for what used to be called "vaginal atrophy." It describes the changes to vulvar, vaginal, and lower urinary tract tissues that occur when estrogen falls: thinning, reduced elasticity, decreased lubrication, changes in pH, and — for many women — recurrent urinary symptoms. Prevalence estimates run 50–70% of postmenopausal women [1].
Desire is a system-level output, not just a hormone number. It integrates estrogen (which supports genital tissue and often mood), testosterone (which contributes to desire in women as well as men), sleep, mood, stress, medications (SSRIs commonly reduce libido), and relationship context. Reducing "low libido" to a single cause misses how it actually works [2].
Testosterone in women is a real hormone, produced in the ovaries and adrenals, that declines gradually with age. The Global Consensus Position Statement on the use of testosterone therapy for women concludes that testosterone therapy — when clinically appropriate — has evidence specifically for hypoactive sexual desire disorder in postmenopausal women [3]. No testosterone product is currently FDA-approved for women in the U.S., so use is off-label and belongs with a licensed provider.
The most treatable piece is often the physical. Local (vaginal) estrogen — low-dose, delivered as a cream, tablet, or ring — is highly effective for GSM and carries minimal systemic absorption. It is described in NAMS guidance as one of the safest and most effective menopause treatments available [1][4]. DHEA (prasterone) and non-hormonal moisturizers/lubricants are additional options a provider may discuss.
of midlife women report low sexual desire that causes distress
Obstetrics & Gynecology — Shifren et al.Local (vaginal) estrogen is the most-effective treatment for GSM. It is available as a cream, tablet, ring, or insert. Systemic absorption is minimal at recommended doses, and current guidance from The Menopause Society and ACOG supports use in most postmenopausal women, including many with a history of breast cancer after specialist consultation [1][4].
DHEA (prasterone) is an FDA-approved intravaginal treatment specifically for painful intercourse due to GSM.
For hypoactive sexual desire that persists after other factors are addressed, a licensed provider may discuss whether testosterone therapy is clinically appropriate, using off-label dosing informed by the Global Consensus Position Statement [3]. Systemic hormone therapy, if being used for other reasons, sometimes also improves desire indirectly.
Educational information only. Prescription decisions are made by a licensed provider based on your individual medical history.
Often yes — and more effectively than most women are told. The physical piece (GSM) responds well to local estrogen or DHEA. The desire piece is a system output that responds to sleep, mood care, relationship work, and — when appropriate — testosterone therapy [1][3].
Local vaginal estrogen at recommended doses has minimal systemic absorption and is considered one of the safest menopause treatments available by The Menopause Society and ACOG. Individual decisions belong with a licensed provider [1][4].
For postmenopausal women with hypoactive sexual desire disorder that causes distress, testosterone therapy — off-label in the U.S. — has evidence and is discussed in the Global Consensus Position Statement. Prescribing is a clinical decision [3].
Painful intercourse (dyspareunia) is a treatable medical symptom. Local estrogen, DHEA, and dedicated moisturizers/lubricants are first-line, and pelvic floor physical therapy helps many women. Talk to a provider — this is fixable more often than not.
No. GSM is treatable. Desire is a system, and systems have levers. The under-treatment rate is a communication problem, not a biology problem.
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Reviewed by the Kindr Health medical team · Last reviewed 2026-07-15.